US-UK Pharmaceuticals: Tariff Relief Through Pricing Reform

Deal Overview

The US and UK have agreed a new sector-specific trade arrangement under which tariffs on British medicines and medical technology exported to the US will be set at 0% for at least three years, giving the UK uniquely preferential treatment at a time of heightened US trade protectionism. In return, the UK has committed to paying around 25% more for innovative medicines through the NHS, marking the first major shift in domestic drug pricing policy in over two decades. The agreement has been framed by both governments as a way to strengthen cross-Atlantic research, development and investment in pharmaceuticals and medtech.³

Trade context

The timing reflects the US administration’s broader turn towards industry-specific tariffs, with President Trump announcing 100% levies on branded or patented drug imports, subject to limited exemptions where companies manufacture in the US. That backdrop significantly increased downside risk for UK-based manufacturers such as AstraZeneca and Merck, both of which paused or cancelled major UK investments while expanding US operations, highlighting the commercial vulnerability of UK production without guaranteed preferential access.⁵

Pharmaceuticals are among the UK’s most valuable exports to the US, worth £11.1bn in the year to end-September and accounting for 17.4% of UK goods exports, making tariff certainty commercially critical.⁶

Legal implications

The deal is legally significant because it directly links trade access to domestic pricing and appraisal frameworks,  meaning the UK was required to reform how the NHS evaluates and pays for medicines as a condition of securing tariff–free access to the US market. This includes increasing the net price paid for innovative medicines by approximately 25%, implement a material change to NICE’s cost-effectiveness (QALY) threshold from around £30,000 to £35,000, and cap rebate clawbacks paid by manufacturers at 15%, down from

1.  Department for, ‘Landmark UK-US Pharmaceuticals Deal to Safeguard Medicines Access and Drive Vital Investment for UK Patients and Businesses’ (GOV.UK December 2025) https://www.gov.uk/government/news/landmark-uk-us-pharmaceuticals-deal-to-safeguard-medicines-access-and-drive-vital-investmentfor-uk-patients-and-businesses.

2.  Simon Jack, ‘US and UK Agree Zero Tariffs Deal on Pharmaceuticals’ BBC (1 December 2025) https://www.bbc.com/news/articles/cn0k520v4xro.

3.  Department for, ‘Landmark UK-US Pharmaceuticals Deal to Safeguard Medicines Access and Drive Vital Investment for UK Patients and Businesses’ (GOV.UK December 2025) https://www.gov.uk/government/news/landmark-uk-us-pharmaceuticals-deal-to-safeguard-medicines-access-and-drive-vital-investmentfor-uk-patients-and-businesses.

4.  Osmond Chia, ‘Trump Announces New Tariffs on Trucks, Drugs and Kitchen Cabinets’ BBC (26 September 2025) https://www.bbc.com/news/articles/crkjreprp3po.

5.   Maggie Fick and Alistair Smout, ‘US, UK to Agree to Zero Tariffs on Pharmaceuticals, Announcement Expected, Sources Say’ Reuters (1 December 2025) https://www.reuters.com/business/healthcare-pharmaceuticals/us-uk-agree-zero-tariffs-pharmaceuticals-announcement-expected-sources-say-2025-12-01/.

6.  Maggie Fick and Alistair Smout, ‘US, UK to Agree to Zero Tariffs on Pharmaceuticals, Announcement Expected, Sources Say’ Reuters (1 December 2025) https://www.reuters.com/business/healthcare-pharmaceuticals/us-uk-agree-zero-tariffs-pharmaceuticals-announcement-expected-sources-say-2025-12-01/.
7.  Maggie Fick and Alistair Smout, ‘US, UK to Agree to Zero Tariffs on Pharmaceuticals, Announcement Expected, Sources Say’ Reuters (1 December 2025) https://www.reuters.com/business/healthcare-pharmaceuticals/us-uk-agree-zero-tariffs-pharmaceuticals-announcement-expected-sources-say-2025-12-01/.

recent rates exceeding 20%. In addition, UK-made medicines, ingredients and medtech will be exempt from future Section 232 and Section 301 US tariffs, reflecting Washington’s preference for locking in sectoral outcomes as its wider tariff powers face legal challenge.⁹

These changes alter the legal and contractual basis on which pharmaceutical companies supply medicines to the NHS, while embedding international trade commitments into domestic procurement and pricing regulation.¹⁰

Commercial impact

From a commercial perspective, the agreement functions as an investment stabiliser. It follows a period in which major firms paused or cancelled UK investments, including Merck’s £1bn UK expansion and AstraZeneca’s paused Cambridge facility, while announcing substantial new US investments.¹¹

This matters because reduced pharmaceutical investment directly disadvantages several stakeholders. For the UK economy, cancelled projects mean lost high-skilled jobs, reduced research capacity and weaker positioning as a global life sciences hub. For pharmaceutical companies operating in the UK, tariff uncertainty and lower domestic pricing reduced the commercial viability of UK-based production, incentivising relocation to jurisdictions with more favourable trade and pricing conditions.¹³

Patients and the NHS are also indirectly affected. Lower investment risks delaying access to innovative medicines and clinical trials, as companies prioritise markets where pricing and regulatory frameworks offer more predictable returns. At the same time, investors face valuation uncertainty, as pricing policy and tariff exposure directly affect revenue forecasts and long-term profitability.¹⁵

8.  Simon Jack, ‘US and UK Agree Zero Tariffs Deal on Pharmaceuticals’ BBC (1 December 2025) https://www.bbc.com/news/articles/cn0k520v4xro.

9.  Maggie Fick and Alistair Smout, ‘US, UK to Agree to Zero Tariffs on Pharmaceuticals, Announcement Expected, Sources Say’ Reuters (1 December 2025) https://www.reuters.com/business/healthcare-pharmaceuticals/us-uk-agree-zero-tariffs-pharmaceuticals-announcement-expected-sources-say-2025-12-01/.

10.   Lisa O’Carroll and Denis Campbell, ‘NHS to Pay 25% More for Innovative Drugs after UK–US Zero-Tariff Deal’ (the GuardianDecember 2025) https://www.theguardian.com/business/2025/dec/01/uk-us-agree-zero-tariff-pharmaceuticals-deal.

11.  Simon Jack, ‘US and UK Agree Zero Tariffs Deal on Pharmaceuticals’ BBC (1 December 2025) https://www.bbc.com/news/articles/cn0k520v4xro.

12.  Department for, ‘Landmark UK-US Pharmaceuticals Deal to Safeguard Medicines Access and Drive Vital Investment for UK Patients and Businesses’ (GOV.UK December 2025) https://www.gov.uk/government/news/landmark-uk-us-pharmaceuticals-deal-to-safeguard-medicines-access-and-drive-vital-investmentfor-uk-patients-and-businesses.

13.   Maggie Fick and Alistair Smout, ‘US, UK to Agree to Zero Tariffs on Pharmaceuticals, Announcement Expected, Sources Say’ Reuters (1 December 2025) https://www.reuters.com/business/healthcare-pharmaceuticals/us-uk-agree-zero-tariffs-pharmaceuticals-announcement-expected-sources-say-2025-12-01/.

14.  Department for, ‘Landmark UK-US Pharmaceuticals Deal to Safeguard Medicines Access and Drive Vital Investment for UK Patients and Businesses’ (GOV.UK December 2025) https://www.gov.uk/government/news/landmark-uk-us-pharmaceuticals-deal-to-safeguard-medicines-access-and-drive-vital-investmentfor-uk-patients-and-businesses.

15.  Lisa O’Carroll and Denis Campbell, ‘NHS to Pay 25% More for Innovative Drugs after UK–US Zero-Tariff Deal’ (the GuardianDecember 2025) https://www.theguardian.com/business/2025/dec/01/uk-us-agree-zero-tariff-pharmaceuticals-deal.

By securing tariff-free access and improving price predictability, the deal reduces these risks, making the UK a more commercially attractive location for pharmaceutical manufacturing, research and investment.¹⁶

Political pressure has been unusually explicit. The US ambassador, Warren Stephens, warned that pharmaceutical companies could “shut down their facilities in the UK” unless pricing reforms were implemented quickly, citing decisions that were becoming “irreversible”. This signals that pricing policy is now a live investment determinant, increasing policy risk for firms and investors and accelerating corporate decisions on where to locate manufacturing and R&D.¹⁸

Outlook

The fiscal consequences remain contested. Estimates suggest the reforms could add around £3bn per year to NHS medicines spending over time, raising questions about long-term affordability despite government assurances of Treasury funding.¹⁹

More broadly, the pharmaceuticals agreement sits within an unfinished Economic Prosperity Deal, with negotiations continuing over standards and non-tariff barriers. The recent US suspension of the bilateral technology deal underscores how sector-specific agreements may be used as leverage in wider trade negotiations. The deal therefore signals a broader shift in trade policy: market access is increasingly secured through domestic regulatory reform, not tariffs alone.

16.  Department for, ‘Landmark UK-US Pharmaceuticals Deal to Safeguard Medicines Access and Drive Vital Investment for UK Patients and Businesses’ (GOV.UK December 2025) https://www.gov.uk/government/news/landmark-uk-us-pharmaceuticals-deal-to-safeguard-medicines-access-and-drive-vital-investmentfor-uk-patients-and-businesses.

17.  Ashley Armstrong, ‘UK Must Pay More for Drugs or Pharma Companies Will Quit Country, US Envoy Says’ (@FinancialTimes5 November 2025) <https://www.ft.com/content/faca5df6-2485-441f-b285-014e2865491b> accessed 27 December 2025.

18.   Ashley Armstrong, ‘UK Must Pay More for Drugs or Pharma Companies Will Quit Country, US Envoy Says’ (@FinancialTimes5 November 2025) https://www.ft.com/content/faca5df6-2485-441f-b285-014e2865491b accessed 27 December 2025.

19.  Lisa O’Carroll and Denis Campbell, ‘NHS to Pay 25% More for Innovative Drugs after UK–US Zero-Tariff Deal’ (the GuardianDecember 2025) https://www.theguardian.com/business/2025/dec/01/uk-us-agree-zero-tariff-pharmaceuticals-deal.

20.  Sophie Inge and others, ‘The UK-US Trade Deal Isn’t Done Yet. Here’s What’s Still on the Table.’ (POLITICO2 December 2025) https://www.politico.eu/article/uk-us-trade-deal-isnt-done-yet-heres-whats-still-on-the-table-steel-cars-pharmaceuticals/ accessed 27 December 2025.

21.  Aime Williams and George Parker, ‘US Suspends Technology Deal with the UK’ (@FinancialTimes15 December 2025) https://www.ft.com/content/afd45e58-5351-4379-8f7e-5788da3d2e20.